



Designation: F2212-02 (Reapproved 2007) Designation: F 2212 – 08<sup>ε1</sup>

## Standard Guide for Characterization of Type I Collagen as Starting Material for Surgical Implants and Substrates for Tissue- Engineered Medical Products (TEMPS)<sup>1</sup>

This standard is issued under the fixed designation F 2212; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon ( $\epsilon$ ) indicates an editorial change since the last revision or reapproval.

---

<sup>ε1</sup> NOTE—~~Formatting and grammar were corrected editorially throughout in April 2007.~~

---

~~Mercury warning was editorially added in April 2008.~~

---

### INTRODUCTION

Collagen-based medical ~~devices~~ products are becoming more prevalent, especially in the area of soft tissue augmentation. The use of collagen in surgery dates back to the late 1800s, with the use of catgut sutures, human cadaveric skin, and fascia. More recently, collagen has been used in hemostatic sponges, dermal equivalents, injectables for soft tissue augmentation, as a matrix for cell-based products and as a vehicle for drug delivery. It is because of the versatility of collagen in medical applications that specific characterizations should be performed as a way to compare materials.

#### 1. Scope

1.1 This guide for characterizing collagen-containing biomaterials is intended to provide characteristics, properties, and test methods for use by producers, manufacturers, and researchers to more clearly identify the specific collagen materials used. With greater than 20 types of collagen and the different properties of each, a single document would be cumbersome. This guide will focus on the characterization of Type I collagen, which is the most abundant collagen in mammals, especially in skin and bone. Collagen isolated from these sources may contain other types of collagen, for example, Type III and Type V. This guide does not provide specific parameters for any collagen product or mix of products or the acceptability of those products for the intended use. The collagen may be from any source, including, but not limited to ~~to~~ animal or cadaveric sources, human cell culture, or recombinant sources. The biological, immunological, or toxicological properties of the collagen may ~~vary~~ vary depending on the source material. The properties of the collagen prepared from each of the above sources must be thoroughly investigated, as the changes in the collagen properties as a function of source materials is not thoroughly understood. This guide is intended to focus on purified Type I collagen as a starting material for surgical implants and substrates for ~~Tissue-Engineered Medical Products~~ tissue engineered medical products (TEMPS); some methods may not be applicable for gelatin nor for tissue implants. This guide may serve as a template for characterization of other types of collagen.

1.2 The biological response to collagen in soft tissue has been well documented by a history of clinical use (1, 2)<sup>2</sup> and laboratory studies (3, 4, 5, ~~216~~). ~~Biocompatibility and appropriateness of use for a specific application(s) is the responsibility of the device manufacturer.~~

~~1.3. Biocompatibility and appropriateness of use for a specific application(s) is the responsibility of the product manufacturer.~~

1.3 **Warning**—Mercury has been designated by EPA and many state agencies as a hazardous material that can cause central nervous system, kidney, and liver damage. Mercury, or its vapor, may be hazardous to health and corrosive to materials. Caution should be taken when handling mercury and mercury-containing products. See the applicable product Material Safety Data Sheet (MSDS) for details and EPA's website (<http://www.epa.gov/mercury/faq.htm>) for additional information. Users should be aware that selling mercury or mercury-containing products, or both, in your state may be prohibited by state law.

1.4 The following precautionary caveat pertains only to the test method portion, Section 5, of this guide. *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory requirements prior to use.*

---

<sup>1</sup> This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.42 on Biomaterials and Biomolecules for TEMPS.

Current edition approved Feb. 1, ~~2007~~ 2008. Published ~~February 2007~~ March 2008. Originally approved in 2002. Last previous edition approved in ~~2002~~ 2007 as F 2212 – 02 (2007).

<sup>2</sup> The boldface numbers in parentheses refer to the list of references at the end of this standard.

## 2. Referenced Documents

### 2.1 ASTM Standards:<sup>3</sup>

- E 1298 Guide for Determination of Purity, Impurities, and Contaminants in Biological Drug Products
- F 619 Practice for Extraction of Medical Plastics
- F 720 Practice for Testing Guinea Pigs for Contact Allergens: Guinea Pig Maximization Test
- F 748 Practice for Selecting Generic Biological Test Methods for Materials and Devices
- F 749 Practice for Evaluating Material Extracts by Intracutaneous Injection in the Rabbit
- F 756 Practice for Assessment of Hemolytic Properties of Materials
- F 763 Practice for Short-Term Screening of Implant Materials
- F 813 Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices
- F 895 Test Method for Agar Diffusion Cell Culture Screening for Cytotoxicity
- F 981 Practice for Assessment of Compatibility of Biomaterials for Surgical Implants with Respect to Effect of Materials on Muscle and Bone
- F 1251 Terminology Relating to Polymeric Biomaterials in Medical and Surgical Devices
- F 1439 Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials
- F 1903 Practice for Testing For Biological Responses to Particles *in vitro*
- F 1904 Practice for Testing the Biological Responses to Particles *in vivo*
- F 1905 Practice For Selecting Tests for Determining the Propensity of Materials to Cause Immunotoxicity
- F 1906 Practice for Evaluation of Immune Responses In Biocompatibility Testing Using ELISA Tests, Lymphocyte Proliferation, and Cell Migration
- F 1983 Practice for Assessment of Compatibility of Absorbable/Resorbable Biomaterials for Implant Applications
- F 2148 Practice for Evaluation of Delayed Contact Hypersensitivity Using the Murine Local Lymph Node Assay (LLNA)

### 2.2 ISO Standards:<sup>4</sup>

- ISO 10993-1 ISO 10993-1 Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing
- ISO 10993-3—Part 3 Tests 10993-3 Tests for Genotoxicity, Carcinogenicity and Reproductive Toxicity
- ISO 10993-9—Part 9
- ISO 10993-9 Framework for Identification and Quantification of Potential Degradation Products
- ISO 10993-10 ISO 10993-10 Biological Evaluation of Medical Devices—Part 10: Tests for Irritation and Delayed-Type Hypersensitivity
- ISO 10993-17—Part 17 ISO 10993-17 Methods for Establishment of Allowable Limits for Leachable Substances Using Health-Based Risk Assessment
- ISO 13408-1: 1998 Aseptic Processing of Health Care Products—Part 1: General Requirements—ISO 13408-1 Aseptic Processing of Health Care Products—Part 1: General Requirements
- ISO 14971 Medical Devices—Application of Risk Management to Medical Devices

### 2.3 EN (European Norm) Documents:<sup>5</sup>

- EN 12442-1 EN 12442-1 Animal Tissues and their Derivatives Utilized in the Manufacture of Medical Devices—Part 1: Analysis and Management of Risk
- EN 12442-2—Part 2 EN 12442-2 Controls on Sourcing, Collection and Handling
- EN 12442-3—Part 3 EN 12442-3 Validation of the Elimination and/or Inactivation of Virus and Transmissible Agents

### 2.4 U. S. Pharmacopeia Documents: U. S. and European Pharmacopeia Documents:<sup>6</sup>

- United States Pharmacopeia (USP), Edition XXIV (24)–XXX (30)
- USP 24/NF30/NF 19 Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
- European Pharmacopeia 5.0

### 2.5 Code of Federal Regulations:<sup>7</sup>

- 21 CFR 312 Investigational New Drug Application
- Code of Federal Regulations, Title 21, Part 820-21 CFR Part 820 Quality System Regulation
- Federal Register Vol. 43, No. 141, Friday, July 21, 1978
- Human Cells, Tissues and Cellular and Tissue-Based Products, Establishment Registration and Listing. 21 CFR Parts 207, 807, and 1271-21 CFR Parts 207, 807, and 1271 Human Cells, Tissues and Cellular and Tissue-Based Products, Establishment Registration and Listing

<sup>3</sup> For referenced ASTM standards, visit the ASTM website, [www.astm.org](http://www.astm.org), or contact ASTM Customer Service at [service@astm.org](mailto:service@astm.org). For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

<sup>4</sup> Available from International Organization for Standardization (ISO), 1 rue de Varembe, Case postale 56, CH-1211, Geneva 20, Switzerland, <http://www.iso.ch>.

<sup>5</sup> Available from European Committee for Standardization, CEN Management Centre 36, rue de Stassart B-1050 Brussels, Belgium.

<sup>5</sup> Available from European Committee for Standardization (CEN), 36 rue de Stassart, B-1050, Brussels, Belgium, <http://www.cenorm.be>.

<sup>6</sup> Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville, MD 20852-1790, <http://www.usp.org>.

<sup>7</sup> Available from U.S. Government Printing Office Superintendent of Documents, 732 N. Capitol St., NW, Mail Stop: SDE, Washington, DC 20401, <http://www.access.gpo.gov>.

Federal Register/Vol. 66, No. 13, Jan 19, 2001/Rules and Regulations, page 5447 Federal Register, Vol. 66, No. 13, Jan 19, 2001/Rules and Regulations, p. 5447

Federal Register, Vol. 72, No. 8, Jan. 12, 2007, pp. 1581–1619, Proposed Rule: Use of Materials Derived from Cattle in Medical Products Intended for Use in Humans and Drugs Intended for Use in Ruminants

Suitability Determination for Donors of Human Cell and Tissue-based Products, 21 CFR 1271 Part C, Proposed Rule 21 CFR Part 1271, Part C Suitability Determination for Donors of Human Cell and Tissue-based Products, Proposed Rule

Current Good Tissue Practice for Manufacturers of Human Cellular and Tissue-Based Products, Inspection and Enforcement. Proposed Rule. Federal Register/Vol. 66, No. 5/January 8, 2001/Proposed Rules, pages pp. 1552-1559

Guidance for Screening and Testing of Donors of Human Tissue Intended for Transplantation, Availability. Federal Register/Vol. 62, No. 145/July 29, 1997/Notices Draft Guidance for Preclinical and Clinical Investigations of Urethral Bulking Agents used in the Treatment of Urinary Incontinence. November 29, 1995. (ODE/DRARD/ULDB), Document No. 850

Guidance for Industry and for FDA Reviewers, Medical Devices Containing Materials Derived from Animal Sources (Except for *In Vitro* Diagnostic Devices), November 6, 1998, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health

CFR 610.13(b); CFR 610.13(b) Rabbit Pyrogen Assay

2.6 *ICH Documents:*<sup>8</sup>

~~International Conference on Harmonization (1997) ICH M3~~ Guidance for Industry M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals 62 FR 62922 (1997)

~~International Conference on Harmonization (1996) ICH S2A~~ Guideline for Industry S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals. 61 FR 18199 (1996)

~~International Conference on Harmonization (1997) Guidance for Industry S2B~~ Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals 62 FR 62472 ICH S2B Guideline for Industry S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals 62 FR 62472 (1997)

~~International Conference on Harmonization (1994) Guideline for Industry S5A~~ Detection of Toxicity to Reproduction for Medicinal Products. 59 FR 48746 ICH S5A Guideline for Industry S5A Detection of Toxicity to Reproduction for Medicinal Products. 59 FR 48746 (1994)

~~International Conference on Harmonization (1996) ICH S5B~~ Guidance for Industry S5B Detection of Toxicity to Reproduction for Medicinal Products: Addendum on Toxicity to Male Fertility. 61 FR 15360 (1996)

~~International Conference on Harmonization (1996) Guideline for Industry S1A~~ The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals. 61 FR 8153 ICH S1A Guideline for Industry S1A The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals. 61 FR 8153 (1996)

~~International Conference on Harmonization (1998) ICH S1B~~ Guidance for Industry S1B Testing for Carcinogenicity of Pharmaceuticals. 63 FR 8983 (1998)

~~International Conference on Harmonization (1995) ICH S1C~~ Guideline for Industry S1C Dose Selection for Carcinogenicity Studies of Pharmaceuticals. 60 FR 11278 (1995)

~~International Conference on Harmonization (1997) ICH S1C(R)~~ Guidance for Industry Addendum to Dose Selection for Carcinogenicity Studies of Pharmaceuticals: Addition of a Limit Dose and Related Notes. 62 FR 64259 (1997)

~~International Conference on Harmonization (ICH) ICH Q1A~~ ICH Harmonized Tripartite Guidance for Stability Testing of New Drug Substances and Products (September 23, 1994)

U.S. Food and Drug Administration (FDA and Committee for Proprietary Medicinal Products (CPMP), 1998 International Conference on Harmonization (ICH), Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, Consensus Guideline ICH Viral Safety Document: Step 5

2.7 *FDA Documents:*<sup>9</sup>

FDA Guideline on Validation of the Limulus Amebocyte Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products and Healthcare Products, DHHS, December 1987

U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), 1993 Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals

U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), 1997 Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, 94D-0259

FDA Interim Guidance for Human and Veterinary Drug Products and Biologicals, Kinetic LAL techniques, DHHS, July 15, 1991

2.8 *AAMI Documents:*<sup>10</sup>

<sup>8</sup> ICH Secretariat, c/o IFPMA, 30 rue de St-Jean, P.O. Box 758, 1211 Geneva 13, Switzerland.

<sup>8</sup> Available from International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), ICH Secretariat, c/o IFPMA, 15 ch. Louis-Dunant, P.O. Box 195, 1211 Geneva 20, Switzerland, <http://www.ich.org>.

<sup>9</sup> Available from the Food and Drug Administration (FDA), 5600 Fishers Ln., Rockville, MD 20857, <http://www.fda.gov>.

<sup>10</sup> Association for the Advancement of Medical Instrumentation, 1110 N. Glebe Rd., Suite 220, Arlington, VA 22201-4795.

~~ANSI/AAMI/ISO 11737-1: 1995~~ ANSI/AAMI/ISO 11737-1: 2006 Sterilization of Medical Devices—Microbiological Methods—Part 1: Estimation of Bioburden on Product  
 ANSI/AAMI/ISO 11737-2: 1998 Sterilization of Medical Devices—Microbiological Methods—Part 2: Tests of Sterility Performed in the Validation of a Sterilization Process  
 AAMI TIR No. 19-1998 Guidance for ANSI/AAMI/ISO 10993-7: 1995, Biological Evaluation of Medical Devices—Part 7: Ethylene Oxide Sterilization Residuals  
 AAMI/ISO 14160-1998 Sterilization of Single-Use Medical Devices Incorporating Materials of Animal Origin—Validation and Routine Control of Sterilization by Liquid Chemical Sterilants  
 AAMI ST67/CDV-2: 1999 Sterilization of Medical Devices—Requirements for Products Labeled “Sterile”

### 2.9 Other References:

~~Draft Guidance for Preclinical and Clinical Investigations of Urethral Bulking Agents Used in the Treatment of Urinary Incontinence, November 29, 1995. (ODE/DRARD/ULDB), Document No. 850.~~

Draft Guidance for Preclinical and Clinical Investigations of Urethral Bulking Agents Used in the Treatment of Urinary Incontinence, November 29, 1995. (ODE/DRARD/ULDB), Document No. 850<sup>11</sup>

Council Directive 93/42/EEC, with Respect to Medical Devices Using Tissues of Animal Origin<sup>12</sup>

Commission Directive 2003/32/EC, with Respect to Medical Devices Manufactured Using Tissues of Animal Origin<sup>12</sup>

EMA/410/01-rev.2, Committee for Proprietary Medical Products, Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medical Products<sup>13</sup>

The European Agency for the Evaluation of Medicinal Products, (EMA), Committee for Proprietary Medicinal Products (CPMP) Guidance Document for Decision Trees for the Selection of Sterilisation Methods (CPMP/QWP/054/98 corr 2000) and Annex to Note for Guidance on Development Pharmaceuticals (CPMP/QWP/155/96)<sup>14</sup>

## 3. Terminology

### 3.1 Definitions:

3.1.1 *adventitious agents, n*—an unintentionally introduced microbiological or other infectious contaminant. In the production of TEMPs, these agents may be unintentionally introduced into the process stream or the final product, or both.

3.1.2 *biocompatibility, n*—a material may be considered biocompatible if the materials performs with an appropriate host response in a specific application (227).

3.1.3 *collagen, n*—Type I collagen is a member of a family of structural proteins found in animals. Type I collagen is part of the fibrillar group of collagens. It derives from the COL1A1 and COL1A2 genes, which express the alpha chains of the collagen. All collagens have a unique triple helical structure configuration of three polypeptide units known as alpha-chains. Proper alignment of the alpha chains of the collagen molecule requires a highly complex enzymatic and chemical interaction *in vivo*. As such, preparation of the collagen by alternate methods may result in improperly aligned alpha chains and, putatively, increase the immunogenicity of the collagen. Collagen is high in glycine, L-alanine, L-proline, and 4-hydroxyproline, low in sulfur, and contains no L-tryptophan. Natural, fibrillar Type I collagen is normally soluble in dilute acids and alkalis. When heated (for example, above approximately 40°C), collagen is denatured to single alpha chains (gelatin). At each end of the chains are short non-helical domains called telopeptides, which are removed in some collagen preparations. Through non-covalent interactions with sites on adjacent helices, fibrillogenesis is achieved. Subsequently, non-reducible cross links are formed. Type I collagen can be associated with Type III and Type V collagen and also with the other non-collagenous proteins like elastin and other structural molecules like glycosaminoglycans and complex lipoproteins and glycoproteins. —Collagens form a family of secreted proteins with predominantly structural function. At least twenty genetically different family members have been identified so far. Several groups of collagen molecules have been classified based upon protein domain structures, macromolecular assemblies, and exon structures of the corresponding genes. All collagens have a unique triple helical structure configuration of three polypeptide units known as alpha-chains. Proper alignment of the alpha chains of the collagen molecule requires a highly complex enzymatic and chemical interaction *in vivo*. As such, preparation of the collagen by alternate methods may result in improperly aligned alpha chains and, putatively, increase the immunogenicity of the collagen. Collagen is high in glycine, L-alanine, L-proline, and 4-hydroxyproline, low in sulfur, and contains no L-tryptophan. When heated (for example, above 60°C), the helical structure of collagen is denatured irreversibly to single  $\alpha$  chains with some  $\beta$  and  $\gamma$  bands (gelatin). At each end of the chains are short non-helical domains called telopeptides, which are removed in some collagen preparations. Through non-covalent interactions with

<sup>11</sup> This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.42 on Biomaterials and Biomolecules for TEMPs.

Current edition approved Feb. 1, 2008. Published March 2008. Originally approved in 2002. Last previous edition approved in 2007 as F 2212 – 02 (2007) <sup>e1</sup>.

<sup>12</sup> Available from Office for Official Publications of the European Communities—European Law, 2, rue Mercier, L-2985, Luxembourg, <http://eur-lex.europa.eu/en/index.htm>.

<sup>13</sup> Available from European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf, London E14 4HB, U.K., <http://www.eudora.org/emea.html>, and <http://www.emea.europa.eu/pdfs/human/bwp/TSE%20NFG%20410-rev2.pdf>.

<sup>14</sup> Available from European Medicines Agency (EMA), 7 Westferry Circus, Canary Wharf, London E14 4HB, U.K., <http://www.eudora.org/emea.html>, and <http://www.emea.europa.eu/pdfs/human/qwp/005498en.pdf>.

sites on adjacent helixes, fibrillogenesis is achieved. Subsequently, non-reducible cross-links are formed. This guide will focus on the characterization of Type I collagen, which is the most abundant collagen in mammals. Type I collagen is part of the fibrillar group of collagens. It derives from the COL1A1 and COL1A2 genes, which express the alpha chains of the collagen. Type I collagen can be associated with Type III and Type V collagen and also with the other non-collagenous proteins like elastin and other structural molecules like glycosaminoglycans and complex lipoproteins and glycoproteins.

3.1.4 *degradation, n*—change in chemical, physical, or molecular structure or appearance (that is, gross morphology) of material.

3.1.5 *endotoxin, n*—~~a high-molecular-weight~~ high molar mass lipopolysaccharide (LPS) complex associated with the cell wall of gram-negative bacteria that is pyrogenic in humans. ~~3.1.5.1 Discussion—Though~~ Though endotoxins are pyrogens, not all pyrogens are endotoxins.

3.1.6 *microorganisms* medical product, n—bacteria, fungi, yeast, mold, viruses, and other infectious agents.

3.1.6.1 *Discussion*—~~Not all microorganisms are infectious or pathogenic.~~ —any diagnostic or therapeutic treatment that may be regulated as a device, biologic, drug or combination product.

3.1.7 *solubility* microorganism, n—a measure of the extent to which the material can be dissolved.

3.1.7.1 *Discussion*—In the context of collagen, refers to the dissociation of the fibrillar aggregates of collagen molecules into a solution. Native Type I collagen which is soluble in dilute acids, but not soluble in neutral pH conditions is termed “insoluble” or “acid-soluble,” while simple aggregates of non-fibrillar collagen soluble in neutral salt solutions are termed “neutral salt-soluble.” Post translational surface charge modifications may alter the solubility of collagen in neutral pH condition. —bacteria, fungi, yeast, mold, viruses, and other infectious agents. However, it should be noted that not all microorganisms are infectious or pathogenic.

3.1.8 *sterilization* solubility, n—the destruction or removal of all microorganisms in or about an object.

3.1.8.1 *Discussion*—~~Examples are by chemical agents, electron beam, gamma irradiation, ultraviolet (UV) exposure, or filtration.~~ —a measure of the extent to which the material can be dissolved. Any colloidal system without obvious phase separation can be considered soluble. In the context of collagen, refers to the dissociation of the fibrillar aggregates of collagen molecules into a solution. Native Type I collagen, which is soluble in dilute acids, but not soluble at physiological conditions, is termed “insoluble” or “acid soluble,” while simple aggregates of non-fibrillar collagen soluble in neutral salt solutions are termed “neutral salt soluble.” Post translational surface charge modifications may alter the solubility of collagen in neutral pH condition.

3.1.9 *sterilization, n*—the destruction or removal of all microorganisms in or about an object, as by chemical agents, electron beam, gamma irradiation, or filtration. If the medical product collagen permits, terminal sterilization is preferential to aseptic processing.

3.1.10 *suspension, n*—the dispersion of a solid through a liquid with a particle size large enough to be detected by purely optical means. <https://standards.iteh.ai/catalog/standards/sist/5072101b-bbcf-44ef-ad40-4e3ae9510a7c/astm-f2212-08e1>

#### 4. Significance and Use

4.1 The objective of this guide is to provide guidance in the characterization of Type I collagen as a starting material for surgical implants and substrates for tissue engineered medical products (TEMPs). This guide contains a listing of physical and chemical parameters that are directly related to the function of collagen. This guide can be used as an aid in the selection and characterization of the appropriate collagen starting material for the specific use. Not all tests or parameters are applicable to all uses of collagen.

4.2 The collagen covered by this guide may be used in a broad range of applications, forms, or applications, medical products, for example (but not limited to) medical devices, tissue- engineered medical products (TEMPs) or ~~cell-, drug-, cell, drug,~~ or DNA-delivery devices for implantation. The use of collagen in a practical application should be based, among other factors, on biocompatibility and physical test data. Recommendations in this guide should not be interpreted as a guarantee of clinical success in any tissue- engineered medical product or drug delivery application.

4.3 The following general areas should be considered when determining if the collagen supplied satisfies requirements for use in TEMPs. These are source of collagen, chemical and physical characterization and testing, and impurities profile.

4.4 The following documents relating to the production, regulation and regulatory approval of TEMPs products should be considered when determining if the collagen supplied satisfies requirements for use in TEMPs:

**FDA CFR:**

**21 CFR 3: Product Jurisdiction:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=3>

**21 CFR 58: Good Laboratory Practice for Nonclinical Laboratory Studies:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58>

**FDA/CDRH CFR and Guidances:**

**21 CFR Part 803: Medical Device Reporting:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=803>

**21 CFR 812: Investigational Device Exemptions:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=812>

**21 CFR 814: Premarket Approval of Medical Devices :**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=814>

**21 CFR 820: Quality System Regulation:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=820>

**Design Control Guidance for Medical Device Manufacturers:**

<http://www.fda.gov/cdrh/comp/designgd.pdf>

**Preproduction Quality Assurance Planning Recommendations for**

**Medical Device Manufacturers (FDA 90-4236):**

<http://www.fda.gov/cdrh/manual/appende.html>

**The Review and Inspection of Premarket Approval Applications under the**

**BioResearch Monitoring Program—Draft Guidance for Industry and FDA Staff:**

<http://www.fda.gov/cdrh/comp/guidance/1602.pdf>

**FDA/CDRH Search Engines:**

**CDRH Guidance Search Engine:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfggp/search.cfm>

**CDRH Premarket Approval (PMA) Search Engine:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>

**CDRH 510(k) Search Engine:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>

**CDRH Recognized STANDARDS Search Engine :**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>

**FDA/CBER CFR and Guidances:**

**21 CFR 312: Investigational New Drug Application :**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312>

**21 CFR 314: Applications for FDA Approval to Market a New Drug:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314>

**21 CFR 610: General Biological Products Standards:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=610>

**21 CFR 1271: Human Cells, Tissues and Cellular and Tissue-Based Products:**

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271>

**Cellular & Gene Therapy Guidances and Other Publications:**

<http://www.fda.gov/cber/genetherapy/gtpubs.htm>

**Human Tissue Guidances and Other Publications:**

<http://www.fda.gov/cber/tissue/docs.htm>

**CBER Product Approval Information:**

<http://www.fda.gov/cber/efoi/approve.htm>

**21 CFR 600, 601 BLA Regulations:**

[http://www.access.gpo.gov/nara/cfr/waisidx\\_07/21cfr7\\_07.html](http://www.access.gpo.gov/nara/cfr/waisidx_07/21cfr7_07.html)

**21 CFR 210, 211 GMP Regulations:**

[http://www.access.gpo.gov/nara/cfr/waisidx\\_07/21cfr210\\_07.html](http://www.access.gpo.gov/nara/cfr/waisidx_07/21cfr210_07.html)

## 5. Chemical and Physical Characterizations

5.1 These methods are suggested assays; however, other validated assay methods may be used. Selection of assay systems will vary, vary depending on the configuration of the collagen (that is, soluble or insoluble). The user should ensure that the method selected is reliable and commonly accepted in protein chemistry. A review of collagen materials may be found in Li, 2000 (78), while a review of the collagen family of proteins may be found in Refs (9-13 and 209-14 ). When selecting an appropriate test method, the user should note that impurities in highly purified collagen fibers can be as low as are low or lower than 1 to 2%, while test method uncertainties can be as high as 10-2 %, so sensitive test methods need to 15% between samples. be utilized. For soluble collagen, the following represents a non-inclusive list of assay systems available: Sodium Dodecyl Sulfate Polyacrylamide Gel